Clinical trial examines oral cancer prevention
from Medical News Today
Oral premalignant lesions are considered risk factors for the development of oral cancer. In an article published online by JAMA Oncology, Dr. William N. William Jr., of the University of Texas MD Anderson Cancer Center, Houston, Dr. Scott M. Lippman, of the University of California, San Diego, and co-authors report the results of a randomized clinical trial that tested if the epidermal growth factor receptor inhibitor erlotinib would reduce oral cancer development in patients with high-risk OPLs defined by specific loss of heterozygosity profiles.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063